Course: Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021
CME Credits: 1.00
Released: 2021-12-15
In a recent study that estimated COVID-19 messenger RNA (mRNA) vaccine effectiveness, we found that the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines were highly effective against SARS-CoV-2 infection before June 2021 among 1,363,180 US veterans who were vaccinated in January and February of 2021. Transmission of the SARS-CoV-2 Delta variant increased rapidly during the summer of 2021, and waning COVID-19 mRNA vaccine effectiveness has been reported. Therefore, we reexamined the estimated effectiveness of the 2 COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) during July to September 2021 among fully vaccinated male veterans aged 65 years or older.
Educational Objective
To identify the key insights or developments described in this article
View Full Course